 BMO Capital has lowered the price target on HCA Healthcare Inc NYSE: HCA to 250 from 275 while keeping the Market Perform rating on the shares after its Q4 results. Analyst Matt Borsch notes execution was very strong, but HCA still contends with near-term issues that include uneven volumes, staffing constraints, and related wage and other inflation. 